At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET
Erasca reported fourth quarter and full year 2025 financial results, highlighted by reduced net losses and a strong cash position bolstered by a $259 million financing in January 2026. The company emphasized early clinical progress in its RAS-targeting pipeline, including partial responses for ERAS-0015 across multiple tumor types, and expanded its licensing rights globally. Phase 1 data for ERAS-0015 and ERAS-4001 are expected in H1 and H2 2026, respectively.
- Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year prior.
- Completed upsized public offering in January 2026, raising $258.8 million in gross proceeds, bringing pro forma cash to $434 million.
- Cash expected to fund operations into H2 2028.
- Net loss decreased to $29.1 million in Q4 2025 from $32.2 million in Q4 2024; full-year net loss improved to $124.5 million from $161.7 million in 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access